Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques.
A new contrast agent for MRI based on recombinant HDL-like nanoparticles has been prepared. It shows a great potential as a contrast agent for atherosclerotic plaques in a relative short time (24 h post-injection) as it is selective for the plaques and is an endogenous molecule. It also can distinguish between different types of plaques as the enhancement obtained is different, depending on plaque composition.
Frias
Juan C
JC
Imaging Science Laboratories, Department of Radiology, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA.
Williams
Kevin Jon
KJ
Fisher
Edward A
EA
Fayad
Zahi A
ZA
D001161:Arteriosclerosis / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D003287:Contrast Media / Q000737:chemistry / Q000494:pharmacology; D005456:Fluorescent Dyes; D019786:Gadolinium DTPA / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007211:Indoles; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000493:pharmacokinetics; D008279:Magnetic Resonance Imaging / Q000379:methods*; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D049329:Nanostructures / Q000737:chemistry*; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000493:pharmacokinetics; D011994:Recombinant Proteins / Q000737:chemistry / Q000493:pharmacokinetics
D003287:Contrast Media; D005456:Fluorescent Dyes; D007211:Indoles; D008075:Lipoproteins, HDL; D010714:Phosphatidylethanolamines; D011994:Recombinant Proteins; C007293:DAPI; D019786:Gadolinium DTPA; C018525:1,2-dimyristoylphosphatidylethanolamine